How to Help Your Patients Save Money on Velphoro: A Provider's Guide to Savings Programs

Velphoro (sucroferric oxyhydroxide) costs approximately $2,000–$2,157 per month at retail with no generic alternative. For nephrologists, dialysis care teams, and other prescribers managing CKD patients on dialysis, understanding the landscape of cost-reduction programs is essential — both for improving patient adherence and for avoiding treatment gaps when cost barriers arise. This guide covers every major savings pathway for Velphoro in 2026.

1. The ESRD PPS Bundle: Most Medicare Patients Pay $0

As of January 1, 2025, phosphate binders including Velphoro are included in the Medicare ESRD Prospective Payment System (PPS) bundle. This is the most important change for your Medicare ESRD patient population:

• For Medicare fee-for-service ESRD patients: Velphoro is dispensed through the dialysis facility with no additional copay or coinsurance for most patients. No traditional pharmacy prescription is needed. The dialysis organization handles the formulary.

• Patients still needing pharmacy prescriptions: Medicare Advantage enrollees, commercially insured patients, and those with pending Medicare eligibility continue to require a written prescription and pharmacy dispensing. These patients need additional savings assistance.

Action for your practice: Audit your active Velphoro prescriptions. Which patients are Medicare ESRD fee-for-service? Redirect them to their dialysis center for dispensing if they are still filling at a retail pharmacy — this eliminates their cost burden immediately.

2. Velphoro Savings Card (Commercially Insured Patients)

The Velphoro Savings Card from Fresenius Medical Care is the most impactful copay reduction tool for commercially insured patients.

• Maximum savings: Up to $1,500 per prescription

• Minimum patient cost: As low as $0 copay

• Eligibility: Commercial insurance only. Not valid with Medicare, Medicaid, VA, or other federal programs as primary payer.

• How to enroll patients: Direct patients to velphorocoupon.com or call 1-877-774-6756. Cards can be printed or downloaded. Your office staff can proactively hand these out at the time of prescribing.

3. Velphoro Access Solutions (Manufacturer Patient Assistance Program)

Velphoro Access Solutions is Fresenius Medical Care's integrated patient support program. It provides multiple services in one application:

• Benefit investigation: The Access Solutions team verifies the patient's pharmacy benefits and provides coverage details to your office.

• Prior authorization initiation: Access Solutions can initiate the PA process on your behalf, reducing your staff's workload.

• Patient assistance (PAP): For eligible uninsured or underinsured patients, Access Solutions may provide Velphoro at reduced or no cost.

• New dialysis patient bridge: Patients new to dialysis with pending Medicare eligibility may receive up to 90 days of Velphoro at no cost during the enrollment gap.

How to submit: Complete the Access Solutions enrollment form with your patient and fax to 1-866-496-8638. Include copies of the patient's insurance card (front and back), your prescriber information, and the Velphoro prescription.

4. Velphoro Concierge Support — Specialty Pharmacy with Home Delivery

For patients with a choice of pharmacy (commercial insurance or certain Medicare Advantage), the Velphoro Concierge Support program through ASPN Pharmacies provides specialty pharmacy dispensing with mail delivery. This is particularly useful for patients who live far from a pharmacy that stocks Velphoro.

• Provider fax line: 888-431-3403 (fax prescription directly here)

• Patient call line: 888-222-5270

• Benefit: Home delivery eliminates the retail pharmacy access problem for patients who cannot find Velphoro locally

5. Third-Party Patient Assistance Organizations

For patients who don't qualify for the manufacturer's programs or need additional help, the following third-party organizations may provide financial assistance for Velphoro:

• PAN Foundation (panfoundation.org): Provides copay/cost assistance for eligible patients with Medicare and other insurance. Recommend this for Medicare patients who still have unaffordable copays after ESRD PPS coverage.

• Prescription Hope (prescriptionhope.com): Advocacy service that accesses manufacturer programs on the patient's behalf. Fixed $70/month service fee per medication. Useful for patients who cannot navigate the process independently.

6. When All Else Fails: Consider Therapeutic Alternatives

If cost barriers cannot be overcome despite exhausting the above programs, consider switching to a lower-cost phosphate binder temporarily or permanently, depending on the clinical picture:

• Generic sevelamer carbonate: $49-$100/month with discount cards. Equally efficacious. Available at all retail pharmacies. Main drawback: higher pill burden (3-4 tablets/meal vs. 1 for Velphoro), which may affect adherence.

• Generic calcium acetate: Under $20/month. Use with caution in hypercalcemia, vascular calcification, or low PTH/adynamic bone disease.

How medfinder Can Help with the Access Challenge

For patients who are commercially insured and need to fill Velphoro through a pharmacy, finding a pharmacy that stocks it is its own challenge. medfinder is a paid service that calls pharmacies near your patient to identify which ones can fill their prescription — reducing the time your staff spends fielding 'I can't find my medication' calls.

Summary: Quick-Reference Guide by Patient Type

• Medicare ESRD fee-for-service: Redirect to dialysis facility → $0 under ESRD PPS

• Commercial insurance: Velphoro Savings Card → $0 copay (up to $1,500). Fax prescription to ASPN for home delivery.

• Medicare Advantage (high copay): PAN Foundation + Access Solutions for additional assistance

• Uninsured / low income: Access Solutions PAP + Prescription Hope; or bridge with generic sevelamer

• New dialysis patient (Medicare pending): Access Solutions bridge program (up to 90 days at no cost)

For a comprehensive provider overview of access challenges and clinical management, see our Velphoro shortage: provider update for 2026.